RxDoctor Payments Data

Ilo Leppik, MD

Neurology · Minneapolis, MNNPI 1538174073

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,451 of the $18,385 with a category attached, or 84.0%. UCB, Inc. accounts for 90.4% of it on its own, with 2 other manufacturers making up the rest. Among neurology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,385in general payments, 2019–2025

Across 25 payments — averaging $735.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$17K
  • UCB SA$2K
  • SK Life Science, Inc.$207
$24,259in research payments, 2019–2025

Across 9 payments — averaging $2695.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$22K
  • Medtronic$2K

What the payments were for

  • Consulting fees$15,45184%
  • Travel & lodging$2,12412%
  • Food & beverage$8104%

General payments by program year

19
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.12$16,628
UCB SA11$1,549
SK Life Science, Inc.2$207

How this compares

$18,385 in reported general payments places this provider in the 90th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$22,031
Medicare patients
75
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)71$199,929
FycompaPerampanel160$198,938
KeppraLevetiracetam47$73,264
Rufinamide48$69,464
LamictalLamotrigine32$65,790
Felbamate170$57,710
BriviactBrivaracetam14$44,467
NayzilamMidazolam48$32,261
Inderal LaPropranolol Hcl13$28,785
DilantinPhenytoin Sodium Extended77$21,405
Carbamazepine ErCarbamazepine135$18,241
OnfiClobazam14$17,480
Lacosamide75$16,779
Levetiracetam340$16,014
Divalproex Sodium ErDivalproex Sodium97$9,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$16,628$76,72962 claims
UCB SAKeppra$1,549$73,26447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 434 neurology providers in Minnesota.

Other neurology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →